Comprehensive multi-omics and functional profiling to fully characterize tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter preclinical program that collects primary tumor samples from consecutively enrolled patients with high-risk hematologic or solid malignancies. Samples undergo integrated multi-omics analyses (genomic, transcriptomic and other molecular profiling), cytogenetics/FISH, and ex vivo functional tests to map tumor features. The aim is to generate a complete diagnostic and chemogenomic profile that could help interpret disease biology and highlight actionable vulnerabilities. Enrollment occurs at participating Italian centers and includes patients with relapsed, refractory, metastatic, or otherwise high-risk disease.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Patients aged one year and over who are referred to the centres involved in the protocol (Azienda Ospedaliero-Universitaria di Parma, University of Parma, University of Perugia and Azienda Ospedali Riuniti Villa Sofia-Cervello of Palermo).
* Patients with an established diagnosis of haematological or solid organ malignancy, including haematological or solid malignancies characteristic of the paediatric age group.
* Patients diagnosed with relapsed, refractory and/or metastatic haematological or solid malignancy. Patients may be enrolled regardless of the extent and type of previous therapy. Patients may also be enrolled if they are undergoing active treatment at the time of evaluation.
* Patients must have the capacity to understand the investigative nature of the study and provide informed consent in writing. For patients under the age of 12 years, consent will be provided by the parent/legal guardian according to international guidelines. For patients aged 12 to 17 years, consent will be provided by the patient and the parent/legal guardian according to the mature minor principle.

Exclusion criteria:

* Patients younger than 1 year old
* Patients with active, uncontrolled infections

Where it's running

• AO Riuniti Villa Sofia-Cervello di Palermo
  Palermo, Palermo, Italy Recruiting
• University of Perugia
  Perugia, Perugia, Italy Recruiting

Study contacts

• Study coordinator: Giovanni Roti, Associate Professor
• Email: giovanni.roti@unipr.it
• Phone: +39 0521 702200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• A resource for collecting cancer data and biospecimens

  This study is creating a resource to collect health information and samples from cancer patients and healthy individuals to help improve cancer prevention and treatment strategies.

  Recruiting at 42 sites University of Nebraska · Greenwood Village, Colorado and 41 other locations · NCT02012699

• Chemogenomic profiling for blood cancers

  This project will test whether detailed genetic and molecular profiling of bone marrow, blood, or tissue samples can better characterize diagnosis and relapse for people with suspected or known blood cancers.

  Recruiting Azienda Ospedaliero-Universitaria di Parma · Parma, PR · NCT07445984

• Multi-omics testing for blood and bone marrow cancers

  This project will test a multi-omics lab approach on bone marrow, blood, biopsy and other fluid samples from people with suspected or known hematologic cancers to see if it can better characterize their disease.

  Recruiting Azienda Ospedaliero-Universitaria di Parma · Parma, PR · NCT07445438

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• IDOV-Immune for advanced solid tumors

  This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.

  Recruiting at 5 sites Phase 1 ViroMissile, Inc. · St Louis, Missouri and 4 other locations · NCT06910657

• Understanding the experiences of patients with chronic cancer treatments

  This study is trying to understand how people with advanced chronic cancer feel about their targeted treatments by having them share their experiences through interviews and creative expressions like art and music.

  Recruiting University of Alberta · Edmonton, Alberta · NCT05645510

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.